Richard Francis sells large TEVA stake (NYSE: TEVA)

Rhea-AI Filing Summary

Teva Pharmaceutical Industries reported insider sales by Richard Francis. The filing shows sales of 447,678 ordinary shares on 02/17/2026 for $15,324,799.05 and 442,935 ordinary shares on 03/03/2026 for $14,333,332.31. The notice also lists a Restricted Share Unit award vesting of 50,223 ordinary shares with a date labeled 03/04/2024 and an entry dated 03/04/2026 under compensation.

Insights

Insider Transaction Counsel

Routine Rule 144 sale notices for reported transactions; compliance focus.

The filing records two reported dispositions by Richard Francis: 447,678 shares on 02/17/2026 for $15,324,799.05 and 442,935 shares on 03/03/2026 for $14,333,332.31. These items are typical Rule 144 sale notices and document the reported sale amounts and proceeds.

Review the timing and source of the shares (reported RSU vesting of 50,223 shares on 03/04/2024) to confirm holding-period and volume limitations. Subsequent filings or broker records will confirm settlement and any compliance with Rule 144 prerequisites.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS INC 390 GREENWICH STREET NEW YORK NY 10013	23393	759442.05	1149812898	03/04/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/04/2024	RESTRICTED SHARE UNIT AWARD VESTING	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			50223	03/04/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
RICHARD FRANCIS 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	02/17/2026	447678	15324799.05
RICHARD FRANCIS 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	03/03/2026	442935	14333332.31

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What sales did Richard Francis report for TEVA?

Richard Francis reported sales of 447,678 shares on 02/17/2026 for $15,324,799.05 and 442,935 shares on 03/03/2026 for $14,333,332.31. These amounts are listed in the Form 144 excerpt provided.

Does the filing show any RSUs for TEVA related to these transactions?

The filing lists a Restricted Share Unit award vesting of 50,223 shares with a date entry of 03/04/2024 and a compensation-related line dated 03/04/2026. The excerpt ties that RSU line to compensation.

Who receives the proceeds from the reported sales?

The excerpt records gross proceeds of $15,324,799.05 and $14,333,332.31 associated with the two reported sales. The filing lists the amounts but does not describe further allocation or use of proceeds.

Is this Form 144 disclosure routine or material?

This Form 144 excerpt documents insider dispositions under Rule 144 and appears routine. It lists share counts and proceeds for two sales; it does not state any additional material events or company operational changes.